Effect of L-Carnitine Supplementation on Lipid Profiles of Patients with Liver Disease: A Systematic Review and Meta-Analysis

Overview

Journal Prev Nutr Food Sci

Date 2020 Jul 18

PMID 32676462

Citations 8

Authors

Amir Abbasnezhad

Amin Hasanavand

Ebrahim Falahi

Sara Kashkooli

Omid Asbaghi

Razieh Choghakhori

Affiliations

Soon will be listed here.

Abstract

Results of previous studies regarding the effect of L-carnitine on lipid profiles in the patients with liver diseases are contradictory. This meta-analysis was performed to assess the effect of L-carnitine on serum levels of low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride (TG), and total cholesterol (TC) in overweight patients with liver diseases. A systematic search was carried out using the Web of Science, PubMed, Scopus, and Cochrane library databases to identify articles published before April 2019 investigating the effects of L-carnitine supplementation on patients with liver disease. There was no language or time limitation for the studies. A meta-analysis was carried out using both the random and fixed effects model where appropriate, and I2 index were used to evaluate heterogeneity. These results indicated that L-carnitine supplementation significantly reduces blood levels of TC and TG in patients with liver disease, whereas carnitine had no effect on the levels of HDL and LDL. The reducing effect of L-carnitine on both TC and TG was found following long-term carnitine supplementation (≥24 weeks), supplementation with doses less than or equal to 2,000 mg/d, and in patients with chronic hepatitis C. This meta-analysis indicates the beneficial effect of L-carnitine on TC and TG in overweight patients with liver disease, particularly patients with chronic hepatitis C, in both long-term and low doses.

Citing Articles

Effects of L-carnitine supplementation on lipid profile in adult patients under hemodialysis: a systematic review and meta-analysis of RCTs.

Karimi M, Pirzad S, Pourfaraji S, Roudsari P, Shirsalimi N, Ahmadizad S Front Med (Lausanne). 2024; 11:1454921.

PMID: 39687901 PMC: 11646722. DOI: 10.3389/fmed.2024.1454921.

Revisiting the Role of Carnitine in Heart Disease Through the Lens of the Gut Microbiota.

Demarquoy J Nutrients. 2024; 16(23.

PMID: 39683637 PMC: 11644639. DOI: 10.3390/nu16234244.

The effects of L-carnitine supplementation on cardiovascular risk factors in participants with impaired glucose tolerance and diabetes: a systematic review and dose-response meta-analysis.

Gheysari R, Nikbaf-Shandiz M, Hosseini A, Rasaei N, Hosseini S, Bahari H Diabetol Metab Syndr. 2024; 16(1):185.

PMID: 39085907 PMC: 11290177. DOI: 10.1186/s13098-024-01415-8.

and Supplementation In Vivo Ameliorates HCD-Induced Steatohepatitis and Dyslipidemia by Regulating Hepatic Metabolism.

Nofal A, AboShabaan H, Fadda W, Ereba R, Elsharkawy S, Hathout H Cells. 2024; 13(9.

PMID: 38727268 PMC: 11083725. DOI: 10.3390/cells13090732.

The effect of L-carnitine supplementation on lipid profile in adults: an umbrella meta-analysis on interventional meta-analyses.

Musazadeh V, Alinejad H, Kouhi Esfahani N, Kavyani Z, Keramati M, Roshanravan N Front Nutr. 2023; 10:1214734.

PMID: 37727632 PMC: 10506516. DOI: 10.3389/fnut.2023.1214734.

References

Malaguarnera M, Vacante M, Avitabile T, Malaguarnera M, Cammalleri L, Motta M . L-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes. Am J Clin Nutr. 2008; 89(1):71-6. DOI: 10.3945/ajcn.2008.26251. View

Carter A, Abney T, Lapp D . Biosynthesis and metabolism of carnitine. J Child Neurol. 1995; 10 Suppl 2:S3-7. View

Hurot J, Cucherat M, Haugh M, Fouque D . Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol. 2002; 13(3):708-714. DOI: 10.1681/ASN.V133708. View

Malaguarnera M, Giugno I, Trovato B, Panebianco M, Siciliano R, Ruello P . Lipoprotein(a) concentration in patients with chronic active hepatitis C before and after interferon treatment. Clin Ther. 1995; 17(4):721-8. DOI: 10.1016/0149-2918(95)80048-4. View

Romano M, Vacante M, Cristaldi E, Colonna V, Gargante M, Cammalleri L . L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin. Dig Dis Sci. 2007; 53(4):1114-21. DOI: 10.1007/s10620-007-9983-1. View

Hoppel C . The role of carnitine in normal and altered fatty acid metabolism. Am J Kidney Dis. 2003; 41(4 Suppl 4):S4-12. DOI: 10.1016/s0272-6386(03)00112-4. View

Speliotes E, Balakrishnan M, Friedman L, Corey K . Treatment of Dyslipidemia in Common Liver Diseases. Clin Gastroenterol Hepatol. 2018; 16(8):1189-1196. PMC: 6558967. DOI: 10.1016/j.cgh.2018.04.023. View

Selimoglu M, Aydogdu S, Yagci R, Huseyinov A . Plasma and liver carnitine status of children with chronic liver disease and cirrhosis. Pediatr Int. 2001; 43(4):391-5. DOI: 10.1046/j.1442-200x.2001.01423.x. View

Bae J, Lee W, Yoon K, Park J, Son H, Han K . Improvement of Nonalcoholic Fatty Liver Disease With Carnitine-Orotate Complex in Type 2 Diabetes (CORONA): A Randomized Controlled Trial. Diabetes Care. 2015; 38(7):1245-52. DOI: 10.2337/dc14-2852. View

10.

Mondola P, Santillo M, De Mercato R, Santangelo F . The effect of L-carnitine on cholesterol metabolism in rat (Rattus bubalus) hepatocyte cells. Int J Biochem. 1992; 24(7):1047-50. DOI: 10.1016/0020-711x(92)90372-8. View

11.

Sayed-Ahmed M, Khattab M, Gad M, Mostafa N . L-carnitine prevents the progression of atherosclerotic lesions in hypercholesterolaemic rabbits. Pharmacol Res. 2001; 44(3):235-42. DOI: 10.1006/phrs.2001.0852. View

12.

Stone N, Robinson J, Lichtenstein A, Merz C, Blum C, Eckel R . 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 63(25 Pt B):2889-934. DOI: 10.1016/j.jacc.2013.11.002. View

13.

Malaguarnera M, Gargante M, Russo C, Antic T, Vacante M, Malaguarnera M . L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis--a randomized and controlled clinical trial. Am J Gastroenterol. 2010; 105(6):1338-45. DOI: 10.1038/ajg.2009.719. View

14.

Abbasnezhad A, Choghakhori R, Kashkooli S, Alipour M, Asbaghi O, Mohammadi R . Effect of L-carnitine on liver enzymes and biochemical factors in hepatic encephalopathy: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2019; 34(12):2062-2070. DOI: 10.1111/jgh.14765. View

15.

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View

16.

Irat A, Aktan F, Ozansoy G . Effects of L-carnitine treatment on oxidant/antioxidant state and vascular reactivity of streptozotocin-diabetic rat aorta. J Pharm Pharmacol. 2003; 55(10):1389-95. DOI: 10.1211/0022357021909. View

17.

Yousefinejad A, Siassi F, Mirshafiey A, Eshraghian M, Koohdani F, Hassan Javanbakht M . Effect of Genistein and L-Carnitine and Their Combination on Gene Expression of Hepatocyte HMG-COA Reductase and LDL Receptor in Experimental Nephrotic Syndrome. Iran J Public Health. 2015; 44(10):1339-47. PMC: 4644578. View

18.

Bechmann L, Hannivoort R, Gerken G, Hotamisligil G, Trauner M, Canbay A . The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2011; 56(4):952-64. DOI: 10.1016/j.jhep.2011.08.025. View

19.

Krahenbuhl S . Carnitine metabolism in chronic liver disease. Life Sci. 1996; 59(19):1579-99. DOI: 10.1016/0024-3205(96)00343-8. View

20.

Lauer G, Walker B . Hepatitis C virus infection. N Engl J Med. 2001; 345(1):41-52. DOI: 10.1056/NEJM200107053450107. View